Cablivi banner image

We continue to monitor the latest government advice regarding COVID-19 and will update this page accordingly.

Latest News and Events

  • The National Institute for Health and Care Excellence (NICE) has recommended the use of CABLIVI in line with its full indication.
    • CABLIVI is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. 
    • To view the full NICE recommendations for CABLIVI, please click here
This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.
Cookie Policy
Accept Cookies